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Mutations inducing resistance to anti–epidermal growth factor receptor (EGFR) therapy may have a clinical impact
even if present in minor cell clones which could expand during treatment. We tested this hypothesis in lung cancer
patients treated with tyrosine kinase inhibitors (TKIs). Eighty-three patients with lung adenocarcinoma treated with
erlotinib or gefitinib were included in this study. The mutational status of KRAS and EGFR was investigated by direct
sequencing (DS). KRASmutations were also assessed bymutant-enriched sequencing (ME-sequencing). DS detected
KRASmutations in 16 (19%) of 83 tumors; ME-sequencing identified all the mutations detected by DS but also muta-
tions in minor clones of 14 additional tumors, for a total of 30 (36%) of 83. KRAS mutations assessed by DS and
ME-sequencing significantly correlated with resistance to TKIs (P = .04 and P = .004, respectively) and significantly
affected progression-free survival (PFS) and overall survival (OS). However, the predictive power of mutations as-
sessed by ME-sequencing was higher than that obtained by DS (hazard ratio [HR] = 2.82, P = .0001 vs HR = 1.98,
P= .04, respectively, for OS; HR= 2.52, P= .0005 vsHR= 2.21, P= .007, respectively, for PFS). Survival outcome of
patients harboring KRAS mutations in minor clones, detected only by ME-sequencing, did not differ from that of pa-
tients with KRASmutations detected by DS. Only KRASmutations assessed byME-sequencing remained an indepen-
dent predictive factor at multivariate analysis. KRASmutations in minor clones have an important impact on response
and survival of patients with lung adenocarcinoma treated with EGFR-TKI. The use of sensitive detection methods
could allow to more effectively identify treatment-resistant patients.
Neoplasia (2009) 11, 1084–1092EGFR, epidermal growth factor receptor; ME-sequencing, mutant-enriched sequenc-
PR, partial response; PFS, progression-free survival; SD, stable disease; TKI, tyrosine
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The development of small-molecule tyrosine kinase inhibitors (TKIs),
such as gefitinib or erlotinib, which specifically inhibit signaling from
the epidermal growth factor receptor (EGFR), has greatly influenced
the treatment of non–small cell lung cancer (NSCLC) patients [1–3],
allowing dramatic responses, even within a short time since the ad-
ministration [4,5]. However, these remarkable responses are limited
to a small subset of patients. A high sensitivity to gefitinib [4,5] or
erlotinib [6] treatment has been reported in EGFR-mutated lung can-
cers. Unfortunately, drug resistance can occur because of additional
mutations in the EGFR gene. The major lesion identified to date is
an EGFR T790M mutation that blocks the binding of erlotinib or
gefitinib to the kinase ATP binding pocket [7,8]. It has recently been
reported that T790M mutations present in small fractions of tumor
cells before therapy are crucial in response to treatment [9]. Indeed,
neoplastic cells carrying this mutation are drug-selected until the tumor
becomes widely resistant. Therefore, use of extremely sensitive analytic
procedures to detect resistant-inducing mutations in minor clones has
been suggested.
Other mechanisms of developing resistance to TKI include constitu-
tive activation of downstream mediators. KRAS, a main downstream
signaling molecule in the EGFR pathway, is frequently affected by
somatic mutations in NSCLC, particularly in lung adenocarcinomas
[10,11]. Most (>95%) KRAS mutations reported in NSCLC were
found at codon 12 [11]. Constitutive activation of Ras proteins by
somatic mutations may render tumor cells independent of EGFR sig-
naling and thereby resistant to EGFR-TKI therapy. Pao et al. reported
for the first time that lung adenocarcinoma patients with KRAS muta-
tions are not responsive to gefitinib or erlotinib [12]. After this seminal
article, numerous studies confirmed this observation [13–18]. In these
studies, the mutational status of KRAS was investigated by direct se-
quencing (DS). Although DS is reliable for screening germ line or preva-
lent somatic mutations, sequencing of low-prevalence mutations is
problematic. In fact, DNA sequencing is useful only when the fraction
of mutated alleles is greater than 20% [19]. In recent years, a number of
more sensitive techniques have been developed. Among them, one of the
most sensitive is mutant-enriched sequencing (ME-sequencing) that can
detect one copy of mutant allele among as many as 103 to 104 copies of
wild-type alleles [20,21]. We have recently used this technique to in-
vestigate the mutational status of KRAS in a large series of colorectal
adenocarcinomas. By means of the enriched procedure, we found muta-
tions in minor clones, undetectable by DS, in 15% of the tumors exam-
ined [22]. The clinical meaning of KRAS mutations affecting minor
clones is still unknown. In the present study, we compared the predictive
power of KRAS mutations assessed by DS or by ME-sequencing on a
series of patients affected by lung adenocarcinomas treated with TKI.
Materials and Methods
Patients and Tissues
Eighty-three patients with histologic diagnosis of lung adenocarcinoma
treated with either erlotinib (55 patients) or gefitinib (28 patients) mono-
therapy at three national referral centers (University of Chieti, Regina
Elena National Cancer Institute, and Istituto Clinico Humanitas) be-
tween 2005 and 2007 were included in this study. Major inclusion cri-
teria encompassed the following: age older than 18 years, advanced
inoperable disease (stage III or IV), documented progressive disease after
at least one previous line of chemotherapy for advanced disease or major
contraindications to chemotherapy treatment, treatment was also al-lowed for patients who had failed a platinum-based chemotherapy regi-
men in either the neoadjuvant or adjuvant setting, and absence of major
comorbidities contraindicating the treatment with an EGFR inhibitor.
Informed consent was obtained from all patients. Treatment consisted
of standard-dose EGFR-TKI (250 mg/die of gefitinib or 150 mg/die of
erlotinib) and was administered as first (n = 14), second (n = 38), or third
or greater (n = 31) line for advanced inoperable disease. Patients’ charac-
teristics are summarized inTable 1A. Response to treatment was evaluated
by standard criteria from the World Health Organization [23] every 8 to
10 weeks; response was confirmed at 4 weeks or longer for patients in
complete response (CR) or partial response (PR). Paraffin-embedded
tumor specimens were obtained from all patients before any therapy.
Samples were cut into 5-μm-thick sections, placed onto glass slides,
and stained with hematoxylin-eosin. Neoplastic areas were manually
microdissected to have at least 70% to 80% of neoplastic cells in the
sample before DNA extraction.
Mutational Analysis of KRAS and EGFR by DS
Genomic DNA was isolated by standard procedures. Genetic analy-
sis of the EGFR gene was performed as previously described [24].Table 1. Clinicopathologic and Biologic Parameters and Clinical Outcome of Patients Treated with
EGFR-TKI (n = 83).PatientsNo. %(A) Clinicopathologic and biologic parameters
Age (years)
Median 65
Range 43–80Sex
Male 48 58
Female 35 42Stage at treatment
III 13 16
IV 70 84Smoking history
Never 29 35
Former 31 37
Current 23 28KRAS mutations
DS
Present 16 19
Absent 67 81Enriched sequencing
Present 30 36
Absent 53 64EGFR mutations
Present 20 24
Absent 63 76(B) Clinical outcome
OR (WHO)
CR 3 4
PR 8 10
SD 26 31
PD 46 55
Overall response (CR + PR) 11 13
DCR (CR + PR + SD) 37 45PFS
Median (95% CI) 5 (2.90–7.10)
Progression-free at 1 year 30 36
Progression-free at 2 years 16 19OS
Median (95% CI) 14 (5.33–22.67)
Alive at 1 year 41 49
Alive at 2 years 30 36PD indicates progressive disease.
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(PCR) amplification of exon 2. The following primers were used for
PCR amplification: 5′-ACTGAATATAAACTTGTGGTAGTTG-
GAGCT-3′; 5′-TAATATGCATATTAAAACAAGATTTACCTC-3′.
The PCR products were purified and subjected to bidirectional se-
quencing using the same primers used for amplification. Samples har-
boring mutations were reamplified and resequenced using the same
experimental conditions. Sequence chromatograms were analyzed by
Mutation Surveior 3.0 (SoftGenetics, State College, PA), followed by
manual review.Mutational Analysis of KRAS by ME-Sequencing
The ME-sequencing assay was used to increase the detection sensi-
tivity of mutations at codon 12. This technique involves a first PCR
reaction, an enzymatic digestion, and a second PCR leading to enrich-
ment of mutant allele before sequencing (Figure 1). The first PCR was
performed using Primer A, 5′-ACTGAATATAAACTTGTGGTAGTT-
GGACCT-3′, and Primer B, 5′-TCAAAGAATGGTCCTGGACC-3′.
Underlined bases represent mismatches from the KRAS DNA sequence
(C to G and G to C, for primers A and B, respectively). The mismatches
introduce a new CCTGG sequence. The restriction enzyme BstNI
(Takara Bio, Inc, Otsu, Shiga, Japan) was used to digest the CCTGG
sequence in the amplicon of the wild type. In contrast, KRAS mutant
alleles were not digested because of the mutations, resulting in the en-
richment of mutant alleles. The first-round PCR amplification was done
for 25 cycles (1minute at 94°C, 40 seconds at 54°C, 40 seconds at 72°C)
using 1× TaqMan buffer, 1.5 mM MgCl2, 800 μM deoxynucleotide tri-
phosphate, 300 nM each primer, 0.3 U of HotStarTaq DNA polymeraseFigure 1. Schematic diagram showing the ME-sequencing method.
See the Materials and Methods section for a detailed description.
A, B, and C are the primers used for PCR amplification. The sym-
bol (•) on the primers indicates a mismatch from the genomicnormal KRAS sequence, which gives rise to a restriction site for the
BstNI enzyme.(Applied Biosystems, Inc, Foster City, CA), and 100 ng of genomic
DNA. After digestion with BstNI, a second PCR was performed to se-
lectively reamplify themutant species that were left uncut byBstNI. The
second-round PCRwas done using Primers A andC, 5′-TAATATGTC-
GACTAAAACAAGATTTACCTC-3′, for 40 cycles (1minute at 94°C,
40 seconds at 54°C, 40 seconds at 72°C). Underlined bases of primer C
represent mismatches from the Kirsten ras DNA sequence (TCG-C to
CAT-T). The product of the second PCR was examined by sequencing
using the conditions reported above.
The method described is a variant of a previously reported protocol
[20,21] based on two enzymatic reactions and detection of mutations
by agarose gel electrophoresis. In our protocol, we use a single enzymatic
reaction, thus avoiding the possibility of false-positive results due to
incomplete digestion, and the mutational status is investigated by se-
quencing that reveals the exact nature of the mutation. The technique
described has been engineered to get the highest sensitivity and speci-
ficity by an accurate selection of reagents and several modifications to
the original protocol. All mutations were confirmed by at least one sec-
ond sequencing of independent PCR products. By serial dilution ex-
periments, we found that this enriched assay could detect up to 0.1%
of mutant DNA in wild-type DNA (data not shown). ME-sequencing
could detect mutations at codon 13 with a sensitivity comparable to
that of DS.
Statistical Methods
Associations between categorical variables were assessed using the χ 2
test or Fisher exact test as appropriate. Logistic regression analysis was
applied to estimate the effect of covariates on disease control rate (DCR;
objective response [OR] + PR + stable disease [SD] vs progressive dis-
ease). Progression-free survival (PFS) and overall survival (OS) were
measured for each patient from the first day of treatment with gefitinib
or erlotinib. Survival curves were estimated using the Kaplan-Meier
method, and differences among them were evaluated by the log-rank
test. Multivariate Cox proportional hazards regression models were
used to assess the effect of covariates on PFS and OS. P < .05 was con-
sidered as significant.
Results
Clinical Variables
OR rate in the population analyzed was 13%, with 45% of patients
achieving DCR (CR, PR, or SD). Approximately half of the patients
went on to receive a subsequent line of chemotherapy treatment on pro-
gression, and all patients were followed up until death. Median PFS for
the entire population was 5 months (95% confidence interval [CI] =
2.9–7.1 months), and median OS was 14 months (95% CI = 5.33–
22.67 months). The percentage of patients alive at 1 and 2 years was
49.4% and 36.2%, respectively. The percentage of progression-free pa-
tients at 1 and 2 years was 36% and 19%, respectively (Table 1B). Fe-
males (42%) had a higher OR than males (23% vs 6%, P = .046) and a
longer median survival (22 vs 6months, P = .003).Never smokers (35%)
had a nonsignificantly higher OR than current or former smokers (21%
vs 9%, P = .1) and a significantly longermedian survival (24 vs 6months,
P = .002).
Mutational Analysis of KRAS and EGFR in
Lung Adenocarcinomas
KRAS mutations were analyzed by DS of PCR products and ME-
sequencing. DS was able to detect KRAS mutations in 16 (19%) of
Figure 2. Representative examples of matched DS and ME-sequencing chromatograms for KRAS analysis of lung adenocarcinoma samples.
(A and B) Tumors in which KRAS mutations (arrows) were visible with both DS and ME-sequencing. (C and D) cases in which the mutations
were detectable only by ME-sequencing (arrows). The enriched procedure is so effective that only the mutated allele is evident.
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mutations detected by DS but detected KRAS mutations in 14 addi-
tional tumor samples for a total of 30 (36%) of 83 (Table 1A and
Figure 2). All mutations were located at codon 12, with the exception
of a single patient in which KRAS was mutated at codon 13 (Table 2).
The 83 tumors were also investigated for mutations in the tyrosine
kinase domain of the EGFR gene. Twenty-one EGFR mutations were
present in 20 (24%) of 83 patients (Table 2). Interestingly, three pa-
tients harbored mutations at both the EGFR (exon 19 deletion, exon
21 point mutation, and double exon 19 and exon 21 mutations, re-
spectively) and the KRAS gene; in such cases, KRAS mutations could
be detected only by ME-sequencing.
Gene Mutations and Response to Treatment
KRAS mutations detected by either method were significantly asso-
ciated with resistance to EGFR-TKI treatment (P = .04 and P = .004
for KRAS mutations assessed by DS and ME-sequencing, respectively;Table 3). In particular, all patients found to be positive by either assay
were nonresponders, indicating that both methods had 100% specific-
ity. Conversely, the sensitivity was significantly higher with the mutant-
enriched assay. The direct method allowed to identify 16 (22%) of
72 nonresponders, whereas the enriched technique revealed the pres-
ence of 30 (42%) of 72 nonresponders (P = .019). As opposed to KRAS
mutations, EGFRmutations were significantly correlated with a higher
likelihood of response (P = .0001; Table 3). In the three patients that
harbored both EGFR and KRASmutations, detected only with the en-
riched method, the response to TKI treatment was SD in one patient
and PD in two patients. Owing to the complete lack of events in re-
sponders, a multivariate logistic regression analysis was conducted by
using DCR instead of OR as the dependent variable. KRAS status as-
sessed byME-sequencing was the only independent predictor of disease
control (P = .019), whereas EGFRmutations were of borderline signifi-
cance (P = .07; Table 4A). When KRAS mutations were assessed by
DS, KRAS status was not retained in the multivariate model, and EGFR
mutations became the only significant factor influencing DCR (data
not shown).Gene Mutations and Survival
Kaplan-Meier analysis of survival curves demonstrated that pa-
tients with KRAS mutations, detected by either method, experiencedTable 2. Gene Mutations in KRAS and EGFR in Lung Adenocarcinomas.Gene and Type of Mutations No. of Mutations Detected
by DSNo. of Mutations Detected
by ME-SequencingKRAS
Codon 12
G34T (G12C) 8 14
G35T (G12V) 3 6
G35A (G12D) 3 6
G34A (G12S) 0 1
G35C (G12A) 1 1
GG34-35TT (G12F) 0 1
Codon 13
G38T (G13V) 1 1EGFR
Exon 19
2235-2249del (E746-A750del) 5 —
2236-2250del (E746-A750del) 3 —
2237-2254del (E746_T751del) 1 —
2240-2257del (L747_P753del) 1 —Exon 21
T2573G (L858R) 10 —
T2582A (L861Q) 1 —Table 3. Gene Mutations and Response to Treatment with TKIs.Gene Mutations Response to TreatmentCR PR SD PD PKRAS mutations (detected by ME-sequencing)
Mutated 0 (0%) 0 (0%) 6 (20%) 24 (80%) .004
Wild-type 3 (6%) 8 (15%) 20 (38%) 22 (41%)KRAS mutations (detected by DS)
Mutated 0 (0%) 0 (0%) 2 (12.5%) 14 (87.5%)
Wild-type 3 (4.5%) 8 (11.9%) 24 (35.8%) 32 (47.8%) .04EGFR mutations
Mutated 3 (15%) 6 (30%) 6 (30%) 5 (25%)
Wild-type 0 (0%) 2 (3.2%) 20 (31.7%) 41 (65.1%) .0001
Figure 3. Overall (A and B) and progression-free (C and D) survival cu
status of KRAS assessed by ME-sequencing (A and C), by DS or only
are statistically significant. All P values refer to log-rank tests. Mont
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in OS were more pronounced when KRAS status was assessed by
ME-sequencing (HR = 2.82, 95% CI = 1.98–8.27, P = .0001 vs
HR = 1.98, 95% CI = 1.04–6.75, P = .04, with ME-sequencing and
DS, respectively). To address the question of whether KRASmutations
detected only byME-sequencing carried the same clinical consequences
as those detected by DS, we divided our study population into three
different groups: KRAS–wild-type patients, patients with KRAS muta-
tions detected by both DS and ME-sequencing, and patients with
KRAS mutations detected only by ME-sequencing. KRAS mutations
detected only by ME-sequencing had the same clinical consequences
in OS as those detected by means of DS (Figure 3B). Indeed, OS
curves for KRAS-mutated patients completely overlapped, regardless
of the detection method, and were significantly different from that of
KRAS–wild-type patients (P = .001). Similar results were obtained for
PFS analysis. KRAS status, as assessed by either method, significantlyTable 4. Multivariate Analysis of Predictive Variables for DCR, PFS, and OS.HR (95% CI) P(A) DCR
KRAS mutations (ME-sequencing) (yes vs no) 3.78 (1.24–11.51) .019
EGFR mutations (no vs yes) 2.94 (0.84–10.29) .07 (NS)
Smoking history (never vs former/current) 1.94 (0.060–6.31) .27 (NS)
Sex (female vs male) 1.28 (0.41–3.99) .67 (NS)(B) PFS
KRAS mutations (ME-sequencing) (yes vs no) 1.87 (1.08–3.24) .02
EGFR mutations (no vs yes) 2.49 (1.15–5.38) .02
Smoking history (never vs former/current) 1.21 (0.87–1.68) .26 (NS)
Sex (female vs male) 1.37 (0.75–2.48) .29 (NS)(C) OS
KRAS mutations (ME-sequencing) (yes vs no) 2.29 (1.23–4.25) .01
EGFR mutations (no vs yes) 2.80 (1.01–7.76) .04
Smoking history (never vs former/current) 1.21 (0.81–1.72) .4 (NS)
Sex (female vs male) 1.79 (0.89–3.64) .1 (NS)NS indicates not significant.rves in lung adenocarcinoma patients according to the mutational
by ME-sequencing (B and D), see test for details. Curve differences
hs indicate months from the beginning of treatment.
Figure 4. Overall (A) and progression-free (B) survival curves in lung adenocarcinoma patients according to the mutational status of KRAS
assessed by DS. Curve differences are statistically significant. All P values refer to log-rank tests. Months indicate months from the
beginning of treatment.
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nounced when KRAS status was assessed by ME-sequencing (HR =
2.52, 95% CI = 1.68–6.36, P = .0005 vs HR = 2.21, 95% CI =
1.45–10.09, P = .007, with ME-sequencing and DS, respectively).
As highlighted above for OS, PFS curves for KRAS-mutated patients
almost completely overlapped, regardless of the detection method,
and were significantly different from that of KRAS–wild-type patients
(P = .005; Figure 3D).
Kaplan-Meier analysis of survival curves also demonstrated a sig-
nificantly longer PFS and OS for patients whose tumors harboredFigure 5. Overall (A) and progression-free (B) survival curves in lun
EGFR. Curve differences are statistically significant. All P values ref
of treatment.EGFR mutations (P = .0002 and P = .0004, respectively; Figure 5).
Interestingly, among patients with EGFR mutations (n = 20), the
three patients who also harbored KRAS mutations (detectable only
by the enriched method) fared significantly worse in OS (P = .003;
Figure 6).
Multivariate analysis using stepwise Cox regression confirmed that
EGFR and KRAS mutations detected by ME-sequencing were the
only two independent predictors of both PFS and OS (Table 4, B
and C ). Conversely, when KRAS mutations were assessed by DS,
KRAS status was not retained in the multivariate model, and EGFRg adenocarcinoma patients according to the mutational status of
er to log-rank tests. Months indicate months from the beginning
Figure 6. Overall curves in patients with lung adenocarcinoma har-
boring EGFR mutations according to the mutational status of KRAS
assessed by ME-sequencing. Curve differences are statistically sig-
nificant. The P value refers to log-rank test. Months indicate months
from the beginning of treatment.
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(data not shown).Discussion
We investigated the predictive role of KRASmutations, detected with
two different methods, in a series of patients affected by lung adeno-
carcinoma undergoing TKI treatment of advanced disease. We com-
pared DS, a widely diffused method for mutational analysis, with
ME-sequencing, an extremely sensitive technique developed to detect
low-prevalence mutations. By DS, mutations were seen in 19% of pa-
tients. The prevalence of KRAS mutations in NSCLC, previously re-
ported in 17 studies investigating the role of KRAS as a marker of
resistance to TKI, has recently been reviewed [25]. Fifteen of these
studies were conducted by DS, for a total of 818 cases examined.
The reported mean frequency of KRAS mutation was 16%, close to
the frequency we observed by DS in our series of cases. The ME-
sequencing method used in the present study was endowed with a
much higher detection power, allowing to reveal KRAS mutations in
36% of lung adenocarcinomas. Thus, in approximately 17% of the
tumors examined, KRAS mutations were present but undetectable by
DS. This can be ascribed to the fact that cells carrying KRASmutations
in these samples represented only a portion of the whole cell popula-
tion. Considering that all samples were microdissected, our results
indicate that, in approximately 17% of lung adenocarcinomas, KRAS
mutations affect subpopulations of tumor cells. Mutant-enriched PCR
methods have mainly been applied to detect neoplastic cells in body
fluids or excretions for early molecular diagnosis of human cancer
[21,26,27]. These very sensitive techniques are generally not used to
detect mutations in primary tumor samples. However, in some circum-
stances, that is, the detection of mutations conferring drug resistance in
small subpopulations of tumor cells, they can be extremely useful. Aselective proliferation of small subclones with mutations inducing drug
resistance has been reported in lung carcinomas treated with gefitinib
[9] and in chronic myelogenous leukemias treated with imatinib [28].
These results indicate that targeted therapies may cause the selection of
mutant cells, and even a small fraction of positive tumor cells at the
beginning of treatment could lead to clinical resistance. Therefore, a
very sensitive assay, rather than DS, is essential to investigate the pres-
ence of mutations conferring drug resistance. Conversely, when sen-
sitive techniques are applied to the screening of mutations associated
with drug sensitivity (i.e., EGFR mutations), they carry the risk of clas-
sifying as positive, cases in which the mutation is present in small sub-
clones, prompting specific treatment even if most of the tumor cells are
indeed insensitive. We believe that our suggestions should be taken into
consideration in future trials.
Previous studies, performed by DS, have shown that KRAS muta-
tions identify a subgroup of NSCLC patients that have an extremely
limited probability of responding to EGFR-targeted treatments. A
recent review and meta-analysis of these data reveals that the test is
highly specific (pooled estimate = 0.94) indicating that CR or PR to
EGFR-TKI are highly unlikely in the presence of a KRAS mutation
[25]. However, the sensitivity of the assay conducted by conventional
methods is quite low (pooled estimate = 0.21), indicating that resis-
tance to EGFR-TKI also occurs in a substantial number of patients
with wild-type KRAS. In our series of patients, KRAS mutations de-
tected by either method were significantly related to lower response
rates. No patient whose tumor harbored a KRAS mutation showed a
CR or PR. This indicates that both methods are highly specific. In
particular, we want to point out that no false-positive results were ob-
served by enriched sequencing, despite the higher number of KRAS
mutations detected. Nevertheless, the sensitivity of the enriched assay
was significantly higher than that obtained by conventional sequencing
(42% vs 22%). Our data indicate that the ME-sequencing could allow
to avoid an inefficient treatment in approximately 20% of patients
found to be negative for KRAS mutations by conventional methods.
Although the enriched assay consistently increases the sensitivity of
KRAS as a predictive marker, resistance still occurs in many patients
with wild-type KRAS, suggesting that other mechanisms including al-
terations that activate the mitogen-activated protein kinase pathway,
such as BRAF and PIK3CA mutations, might hinder the effectiveness
of anti-EGFR therapy. This has recently been shown in metastatic colo-
rectal cancer patients treated with anti-EGFR monoclonal antibodies
(cetuximab and panitumumab) [29,30]. Because it has been reported
that DCR may be a more powerful predictor of survival than tumor
shrinkage, we decided to perform a multivariate analysis using DCR as
the dependent variable.Only theKRAS status assessed byME-sequencing
was found to be an independent predictor of disease control.
Kaplan-Meier survival analysis showed that KRAS mutations de-
tected by either method significantly impacted on PFS and OS. How-
ever, the predictive power of the enriched procedure was by far superior
in both HR and P value. When the study population was divided ac-
cording to the KRAS status investigated with the two techniques, it
clearly emerged that KRASmutations detected only by ME-sequencing
had similar consequences on both OS and PFS as those detected by
DS. This suggests that subpopulations of tumor cells carrying KRAS
mutations may be drug-selected and rapidly expand, making the tumor
resistant to TKI. A multivariate analysis showed that only KRASmuta-
tions detected by ME-sequencing and EGFR mutations were indepen-
dent predictors for TKI treatment in both PFS and OS. The impact of
KRAS mutations with survival in TKI-treated lung cancer patients has
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analysis, KRASmutations were found to be associated with significantly
decreased PFS and/or OS [14–18]. At multivariate analysis, KRASmu-
tations were found to be associated with PFS in the study of Massarelli
et al. [16], whereas Miller et al. did not report any significant correla-
tion [17]. Our results are in keeping with most of these data and sug-
gest that the use of a very sensitive method can improve the prognostic/
predictive power of the KRAS marker.
We previously reported for the first time that KRAS and EGFR mu-
tations are mutually exclusive events in lung adenocarcinomas [24,31].
In these studies, KRAS mutations were investigated by allele-specific
oligoprobe hybridization, which, in our hands, has sensitivity similar
to that of DS. In the present study, when KRAS status was assessed by
ME-sequencing, we found three cases with concomitant KRAS and
EGFR mutations. Because KRASmutations in these cases were not de-
tectable by DS, we speculate that they were present in subpopulations
of these tumors. This observation may be clinically relevant, in that pa-
tients carrying both mutations were resistant to TKI treatment and
showed anOS significantly shorter than that of patients with onlyEGFR
mutations. Our results suggest that the presence of KRASmutations in
minor clones can overcome the effect of EGFR mutations, inducing
tumor resistance.
Because mutations in the KRAS gene were found to be a marker of
response to anti-EGFR antibodies (cetuximab, panitumumab) in colo-
rectal cancer patients, we recently decided to evaluate the prevalence
of KRASmutations detected by DS and ME-sequencing on a series of
90 colorectal carcinomas [22]. The frequency of KRASmutations was
39% by using the direct method and 54% by means of the enriched
assay. These data indicate that also in approximately 15% of colorectal
adenocarcinomas, KRAS mutations in minor clones are present and
may hamper the effect of anti-EGFR treatments.
In conclusion, our data suggest that in future prospective studies, the
use of more sensitive methods, such as ME-sequencing, could allow to
more effectively identify patients resistant to anti-EGFR therapy.References
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